APYX — Apyx Medical Share Price
Last trade - 00:00- $80.72m
- $67.91m
- $44.51m
- 48
- 37
- 19
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.42 | ||
| Price to Tang. Book | 2.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.43% | ||
| Return on Equity | -40.23% | ||
| Operating Margin | -34.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 16.61 | 28.23 | 27.71 | 48.52 | 44.51 | 53.31 | 62.34 | 34.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Apyx Medical Corporation is an advanced energy technology company. The Company operates through two segments: Advanced Energy and OEM. Its Advanced Energy product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. These product lines consist of a multifunction generator, a handpiece, and a supply of helium gas. Its primary focus is on the cosmetic surgery market where Renuvion offers plastic surgeons, fascial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. The Company designs, develops, and manufactures electrosurgical equipment by producing generators and related accessories for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies with the need for its energy-based designs. Its wholly owned subsidiary is Apyx Bulgaria, EOOD.
Directors
- Andrew Makrides CHM (79)
- Charles Goodwin CEO (55)
- John Andres VCH (63)
- Tara Semb CFO (51)
- Todd Hornsby EVP (45)
- Moshe Citronowicz SVP (68)
- Lawrence Waldman LED (75)
- Wendy Levine DRC
- Minnie Baylor-Henry IND (73)
- Michael Geraghty IND (73)
- Craig Swandal IND (58)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- December 3rd, 1982
- Public Since
- July 22nd, 1983
- No. of Shareholders
- 600
- No. of Employees
- 276
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 34,643,855
- Address
- 5115 Ulmerton Rd, CLEARWATER, 33760-4004
- Web
- https://apyxmedical.com/
- Phone
- +1 7273842323
- Auditors
- RSM US LLP
Latest News for APYX
Upcoming Events for APYX
Q4 2023 Apyx Medical Corp Earnings Release
Q1 2024 Apyx Medical Corp Earnings Release
Similar to APYX
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 18:02 UTC, shares in Apyx Medical are trading at $2.33. This share price information is delayed by 15 minutes.
Shares in Apyx Medical last closed at $2.33 and the price had moved by +25.95% over the past 365 days. In terms of relative price strength the Apyx Medical share price has outperformed the S&P500 Index by +11.61% over the past year.
The overall consensus recommendation for Apyx Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Apyx Medical does not currently pay a dividend.
Apyx Medical does not currently pay a dividend.
Apyx Medical does not currently pay a dividend.
To buy shares in Apyx Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.33, shares in Apyx Medical had a market capitalisation of $80.72m.
Here are the trading details for Apyx Medical:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: APYX
Based on an overall assessment of its quality, value and momentum Apyx Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Apyx Medical is $4.75. That is 103.86% above the last closing price of $2.33.
Analysts covering Apyx Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.42 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Apyx Medical. Over the past six months, its share price has underperformed the S&P500 Index by -67.8%.
As of the last closing price of $2.33, shares in Apyx Medical were trading -42.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Apyx Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Apyx Medical's management team is headed by:
- Andrew Makrides - CHM
- Charles Goodwin - CEO
- John Andres - VCH
- Tara Semb - CFO
- Todd Hornsby - EVP
- Moshe Citronowicz - SVP
- Lawrence Waldman - LED
- Wendy Levine - DRC
- Minnie Baylor-Henry - IND
- Michael Geraghty - IND
- Craig Swandal - IND